« Back
Home /
PSMA-ligand-1

PSMA-ligand-1

Item no.	DCC-DC23004-250mg
Manufacturer	DCChemicals
CASRN	1610413-97-2
Amount	250 mg
Quantity options	100 mg 1 g 250 mg
Category	Reagents & Chemicals Amino Acid Derivates general
Type	Amino Acid Derivates
Specific against	other
Smiles	O(C([C@H](CCCCNC(NCC1C=CC(CC(=O)O)=CC=1)=O)NC(N[C@H](C(=O)OC(C)(C)C)CCC(=O)OC(C)(C)C)=O)=O)C(C)(C)C
Available
Manufacturer - Applications	PSMA ligand-tubulysin compounds represent a cutting-edge approach to targeted cancer therapy, combining the precision of PSMA targeting with the potent cytotoxicity of tubulysin. This strategy holds significant promise for improving outcomes in prostate cancer and other PSMA-expressing malignancies, offering a highly specific and effective treatment option with reduced systemic toxicity. As research progresses, these compounds could play a transformative role in the field of oncology.
Molecular Weight	678, 813370227814

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 250 mg

available

Delivery expected until 9/25/2025

Compare

Add to wishlist

Get an offer

Request delivery time